Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?
@article{Mitsumoto2014ClinicalTI, title={Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?}, author={H. Mitsumoto and B. Brooks and V. Silani}, journal={The Lancet Neurology}, year={2014}, volume={13}, pages={1127-1138} }
Amyotrophic lateral sclerosis (ALS) is one of the most rapidly progressive neurodegenerative diseases of unknown cause. Riluzole is the only drug that slows disease progression. More than 50 randomised controlled trials (RCTs) of proposed disease-modifying drugs have failed to show positive results in the past half-century. In the past decade, at least 18 drugs have been tested in large phase 2 or 3 RCTs, including lithium, which was tested in several RCTs. Potential reasons for the negative… CONTINUE READING
Topics from this paper
Paper Mentions
170 Citations
Advances in disease-modifying pharmacotherapies for the treatment of amyotrophic lateral sclerosis
- Medicine
- Expert opinion on pharmacotherapy
- 2020
- 3
The clinical trial landscape in amyotrophic lateral sclerosis—Past, present, and future
- Medicine
- Medicinal research reviews
- 2020
- 11
A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies
- Medicine
- Expert opinion on drug discovery
- 2015
- 23
Shortcomings in the Current Amyotrophic Lateral Sclerosis Trials and Potential Solutions for Improvement
- Medicine
- Front. Neurol.
- 2017
- 18
- PDF
Stem cell treatments for amyotrophic lateral sclerosis: a critical overview of early phase trials
- Medicine
- Expert opinion on investigational drugs
- 2019
- 10
Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection
- Medicine
- Expert opinion on pharmacotherapy
- 2016
- 11
Clinical trials in the ALS syndrome: it is time for change
- Medicine
- Journal of Neurology, Neurosurgery, and Psychiatry
- 2019
- 2
Edaravone in Amyotrophic Lateral Sclerosis’Lessons from the Clinical Development Program and the Importance of a Strategic Clinical Trial Design
- Medicine
- 2018
- 3
- PDF
Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs
- Medicine
- Medicinal research reviews
- 2019
- 60
References
SHOWING 1-10 OF 103 REFERENCES
Of mice and men: Reconciling preclinical ALS mouse studies and human clinical trials
- Medicine
- Annals of neurology
- 2003
- 84
Current pharmacological management of amyotropic lateral sclerosis and a role for rational polypharmacy
- Medicine
- 2004
- 21
Preventing familial amyotrophic lateral sclerosis: Is a clinical trial feasible?
- Medicine
- Journal of the Neurological Sciences
- 2006
- 19
A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.
- Medicine
- The New England journal of medicine
- 1994
- 1,771
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
- Medicine
- The Lancet Neurology
- 2007
- 555
Can selection of rapidly progressing patients shorten clinical trials in amyotrophic lateral sclerosis?
- Medicine
- Archives of neurology
- 2006
- 32
- PDF
Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis
- Medicine
- Neurology
- 2011
- 63
Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials
- Medicine
- Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases
- 2004
- 106